Surface chemistry company AnteoTech (ASX:ADO) began an evaluation of AnteoBind NXT with Indian biotech firm Vidcare Innovations for potential inclusion in their blood diagnostic test product lineup, according to a Tuesday filing with the Australian bourse.
Vidcare agreed to negotiate a supply agreement for the binding activation solution, contingent upon successful evaluations, to support their planned product launch in early 2025, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments